Download PDF
Aktuelle Rheumatologie 2021; 46(01): 36-41
DOI: 10.1055/a-1301-1793
Übersichtsarbeit

Gicht: aktuelle Epidemiologie, Komorbiditäten, Komplikationen und sozioökonomische Konsequenzen

Gout: Current Epidemiology, Comorbidities, Complications and Socioeconomic Consequences
Uta Kiltz 
1   Rheumazentrum Ruhrgebiet, Herne, Deutschland
2   Medizinische Fakultät, Ruhr-Universität Bochum, Bochum, Deutschland
,
Verena Buschhorn-Milberger
1   Rheumazentrum Ruhrgebiet, Herne, Deutschland
2   Medizinische Fakultät, Ruhr-Universität Bochum, Bochum, Deutschland
,
Kristina Vaupel
1   Rheumazentrum Ruhrgebiet, Herne, Deutschland
2   Medizinische Fakultät, Ruhr-Universität Bochum, Bochum, Deutschland
,
Jürgen Braun
1   Rheumazentrum Ruhrgebiet, Herne, Deutschland
2   Medizinische Fakultät, Ruhr-Universität Bochum, Bochum, Deutschland
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Die Gicht gehört neben der rheumatoiden Arthritis zu den häufigsten Ursachen von Gelenkentzündungen. Als metabolisch bedingte Erkrankung geht sie meist mit Hyperurikämie und der Ablagerung von Uratkristallen in Gelenken, Sehnen und Weichteilgeweben einher, wodurch Entzündungszustände ausgelöst werden können. Die Gichtarthritis tritt weltweit insbesondere in den Industrieländern mit steigender Prävalenz auf (weltweit 0,6%), wobei die größte Häufigkeit bei den Maoris in Ozeanien (bis zu 10%) gemessen wurde. In Deutschland tritt die Gicht altersabhängig mit einer Prävalenz von 1,63% auf, wobei Männer ungefähr dreimal so häufig wie Frauen betroffen sind. Kardiovaskuläre und vor allem renale Komorbiditäten können zu vermehrten Komplikationen und einer erhöhten Sterblichkeit von Patienten mit Gicht führen. Grundsätzlich haben Gichtpatienten eine erhöhte Mortalität im Vergleich zur Gesamtbevölkerung. Die zunehmende Inzidenz führt zu steigenden Gesundheitskosten, besonders durch vermehrte Hospitalisierungen. Darüber hinaus wurden bei Gichtpatienten mehr Arbeitsunfähigkeitstage sowie reduzierte Erwerbsfähigkeit mit entsprechenden volkswirtschaftlichen Konsequenzen nachgewiesen.

Abstract

Along with rheumatoid arthritis, gout is the most common cause of arthritis. Being a metabolic disease, it is usually associated with hyperuricemia and the deposition of urate crystals in joints, tendons and soft tissues, which can trigger inflammatory conditions. Gouty arthritis occurs worldwide with increasing prevalence (0.6% worldwide), especially in industrialised countries, with the greatest incidence being measured among the Maoris in Oceania (up to 10%). In Germany, gout occurs with a prevalence of 1.63%, depending on age, with men being affected about 3 times as often as women. Cardiovascular and, in particular, renal comorbidities can lead to increased complications and increased mortality in patients with gout. Basically, gout patients have an increased mortality compared with the general population. The increasing incidence leads to rising health costs, especially through increased hospitalisations. In addition, more days of incapacity for work and reduced earning capacity with the corresponding economic consequences were demonstrated in gout patients.

Schlüsselwörter

Gicht - Epidemiologie - sozioökonomisch - Komorbiditäten - Komplikationen

Key words

gout - epidemiology - socioeconomic - comorbidities - complications


Publication History

Article published online:
15 December 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Kiltz U, Alten R, Fleck M. et al. Full version of the S2e guidelines on gouty arthritis: Evidence-based guidelines of the German Society of Rheumatology (DGRh). Z Rheumatol 2016; 75: 11-60
    PubMedGoogle Scholar
  • 2 Smith E, Hoy DG, Cross M. et al. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 1462-1469
    CrossrefPubMedGoogle Scholar
  • 3 Richette P, Bardin T. Gout. Lancet 2010; 375: 318-328
    CrossrefPubMedGoogle Scholar
  • 4 Choi HK, Mount DB, Reginato AM. et al. Pathogenesis of gout. Ann Intern Med 2005; 143: 499-516
    CrossrefPubMedGoogle Scholar
  • 5 Kuo CF, Grainge MJ, Mallen C. et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015; 74: 661-667
    CrossrefPubMedGoogle Scholar
  • 6 Wijnands JM, Viechtbauer W, Thevissen K. et al. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol 2015; 30: 19-33
    CrossrefPubMedGoogle Scholar
  • 7 Ko YC, Wang TN, Tsai LY. et al. High prevalence of hyperuricemia in adolescent Taiwan aborigines. J Rheumatol 2002; 29: 837-842
    PubMedGoogle Scholar
  • 8 Klemp P, Stansfield SA, Castle B. et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22-26
    CrossrefPubMedGoogle Scholar
  • 9 Kuo CF, Grainge MJ, Zhang W. et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 2015; 11: 649-662
    CrossrefPubMedGoogle Scholar
  • 10 COPCORD. Community Oriented Program for Control of Rheumatic Diseases (COPCORD). In; 2020
  • 11 Elfishawi MM, Zleik N, Kvrgic Z. et al. The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years. J Rheumatol 2018; 45: 574-579
    CrossrefPubMedGoogle Scholar
  • 12 Mattiuzzi C, Lippi G. Recent updates on worldwide gout epidemiology. Clin Rheumatol 2020; 39: 1061-1063
    CrossrefPubMedGoogle Scholar
  • 13 Hak AE, Curhan GC, Grodstein F. et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis 2010; 69: 1305-1309
    CrossrefPubMedGoogle Scholar
  • 14 Evans PL, Prior JA, Belcher J. et al. Obesity, hypertension and diuretic use as risk factors for incident gout: a systematic review and meta-analysis of cohort studies. Arthritis Res Ther 2018; 20: 136
    CrossrefPubMedGoogle Scholar
  • 15 Choi HK, Atkinson K, Karlson EW. et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-1103
    CrossrefPubMedGoogle Scholar
  • 16 Choi HK, Atkinson K, Karlson EW. et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277-1281
    CrossrefPubMedGoogle Scholar
  • 17 Bruderer S, Bodmer M, Jick SS. et al. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol 2014; 66: 185-196
    CrossrefPubMedGoogle Scholar
  • 18 Choi HK, Soriano LC, Zhang Y. et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344: d8190
    CrossrefPubMedGoogle Scholar
  • 19 Jaeschke L, Steinbrecher A, Greiser KH. et al. Erfassung selbst berichteter kardiovaskulärer und metabolischer Erkrankungen in der NAKO Gesundheitsstudie: Methoden und erste Ergebnisse. Bundesgesundheitsblatt 2020; 1-13
    PubMedGoogle Scholar
  • 20 Kiltz U, Perez-Ruiz F, Uhlig T. et al. The Prevalence and Incidence of Gout, Its Associated Comorbidities and Treatment Pattern: An Epidemiological Study from Germany. Arthritis Rheumatol 2018; 70: 1131
    PubMedGoogle Scholar
  • 21 Pisaniello HL, Lester S, Gonzalez-Chica D. et al. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study. Arthritis Res Ther 2018; 20: 143
    CrossrefPubMedGoogle Scholar
  • 22 Dehlin M, Drivelegka P, Sigurdardottir V. et al. Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther 2016; 18: 164
    CrossrefPubMedGoogle Scholar
  • 23 Chen-Xu M, Yokose C, Rai SK. et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol 2019; 71: 991-999
    Google Scholar
  • 24 Doherty M, Jansen TL, Nuki G. et al. Gout: why is this curable disease so seldom cured?. Ann Rheum Dis 2012; 71: 1765-1770
    CrossrefPubMedGoogle Scholar
  • 25 Richette P, Doherty M, Pascual E. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 29-42
    CrossrefPubMedGoogle Scholar
  • 26 Kuo CF, Grainge MJ, Mallen C. et al. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 2016; 75: 210-217
    CrossrefPubMedGoogle Scholar
  • 27 Richette P, Perez-Ruiz F, Doherty M. et al. Improving cardiovascular and renal outcomes in gout: what should we target?. Nat Rev Rheumatol 2014; 10: 654-661
    CrossrefPubMedGoogle Scholar
  • 28 Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum 2020; 50: S11-S16
    CrossrefPubMedGoogle Scholar
  • 29 Grayson PC, Kim SY, LaValley M. et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63: 102-110
    CrossrefPubMedGoogle Scholar
  • 30 Wang J, Qin T, Chen J. et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One 2014; 9: e114259
    CrossrefPubMedGoogle Scholar
  • 31 Disveld IJM, Zoakman S, Jansen T. et al. Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. Clin Rheumatol 2019; 38: 1385-1391
    CrossrefPubMedGoogle Scholar
  • 32 Kim HJ, Ahn HS, Kim J. et al. Cardiovascular event associated with initiating allopurinol and febuxostat- Acute gout attack and cardiovascular gout attack. Ann Rheum Dis 2020; OP0168: 106
    PubMedGoogle Scholar
  • 33 Ridker PM, Everett BM, Thuren T. et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377: 1119-1131
    CrossrefPubMedGoogle Scholar
  • 34 Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012; 125: e671
    PubMedGoogle Scholar
  • 35 Srivastava A, Kaze AD, McMullan CJ. et al. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am J Kidney Dis 2018; 71: 362-370
    CrossrefPubMedGoogle Scholar
  • 36 Odden MC, Amadu AR, Smit E. et al. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988–1994 and 1999–2002. Am J Kidney Dis 2014; 64: 550-557
    CrossrefPubMedGoogle Scholar
  • 37 Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles. Am J Kidney Dis 2010; 56: 247-250
    CrossrefPubMedGoogle Scholar
  • 38 White WB, Saag KG, Becker MA. et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 2018; 378: 1200-1210
    CrossrefPubMedGoogle Scholar
  • 39 Al-Abdouh A, Khan SU, Barbarawi M. et al. Effects of Febuxostat on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mayo Clin Proc Innov Qual Outcomes 2020; 4: 434-442
    CrossrefPubMedGoogle Scholar
  • 40 Latourte A, Soumare A, Bardin T. et al. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Rheum Dis 2018; 77: 328-335
    CrossrefPubMedGoogle Scholar
  • 41 Ungprasert P, Srivali N, Thongprayoon C. Gout is not associated with a lower risk of Parkinson’s disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 2015; 21: 1238-1242
    CrossrefPubMedGoogle Scholar
  • 42 Howren A, Bowie D, Choi HK et al. Epidemiology of depression and anxiety in gout: A systematic review and metaanalysis. J Rheumatol 2020; 10.3899/jrheum.190974
  • 43 Jia Z, Zhang X, Kang S. et al. Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies. Diabetes Res Clin Pract 2013; 101: 88-96
    CrossrefPubMedGoogle Scholar
  • 44 Singh JA, Cleveland JD. Serious Infections in People with Gout in the United States: A National Study of Incidence, Time-trends and Outcomes. Arthritis Care Res (Hoboken) 2020; doi: 10.1002/acr.24201
  • 45 Fisher MC, Rai SK, Lu N. et al. The unclosing premature mortality gap in gout: a general population-based study. Ann Rheum Dis 2017; 76: 1289-1294
    CrossrefPubMedGoogle Scholar
  • 46 D’silva K, Yokose C, Lu L. et al. Sex-specific U-shaped relationship between serum urate and mortality in the United States general population. Ann Rheum Dis 2020; OP0015: 10-11
    CrossrefPubMedGoogle Scholar
  • 47 Singh JA, Yu S. Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study. J Rheumatol 2016; 43: 1581-1588
    CrossrefPubMedGoogle Scholar
  • 48 Sigurdardottir V, Drivelegka P, Svard A. et al. Work disability in gout: a population-based case-control study. Ann Rheum Dis 2018; 77: 399-404
    CrossrefPubMedGoogle Scholar
  • 49 Morlock R, Flores NM, Annunziata K. et al. Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012–2013 National Health and Wellness Survey. Value Health 2015; 18: A640-A641
    CrossrefPubMedGoogle Scholar
  • 50 Wood R, Fermer S, Ramachandran S. et al. Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity. J Rheumatol 2016; 43: 1897-1903
    CrossrefPubMedGoogle Scholar
  • 51 Kiltz U, Smolen J, Bardin T. et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 2017; 76: 632-638
    CrossrefPubMedGoogle Scholar